Bayer AG is yet to see consumers turning to private label OTCs and away from branded products due to growing cost of living pressures. But preparing for such an eventuality is “very high” on the company’s agenda, according to Consumer Health business head Heiko Schipper.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?